Gene expression profiling in rat liver treated with compounds inducing phospholipidosis

Toxicology and Applied Pharmacology

Volumn 229, Issue 3, 2008, Pages 290-299

  Hirode, Mitsuhiro ^a,b   Ono, Atsushi ^b,c   Miyagishima, Toshikazu ^b   Nagao, Taku ^d   Ohno, Yasuo ^c   Urushidani, Tetsuro ^b,e  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^d Food Safety Commission of Japan   (Japan)

^e DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

Author keywords

Liver; Phospholipidosis; Principal component analysis; Rat; Toxicogenomics

Indexed keywords

2 BROMOETHYLAMINE; AMIODARONE; AMITRIPTYLINE; CARBON TETRACHLORIDE; CHLORAMPHENICOL; CHLORPROMAZINE; CLOMIPRAMINE; COUMARIN; DILTIAZEM; ETHIONAMIDE; GENTAMICIN; HYDROXYZINE; IMIPRAMINE; KETOCONAZOLE; METFORMIN; PERHEXILINE; PROMETHAZINE; TAMOXIFEN; TETRACYCLINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DATA BASE; DOSE RESPONSE; GENE EXPRESSION; HISTOPATHOLOGY; LIPIDOSIS; LIVER FUNCTION; MALE; NONHUMAN; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; RAT; TIME;

ANIMALS; DATABASES, GENETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; LIVER; MALE; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; PHOSPHOLIPIDS; PRINCIPAL COMPONENT ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TOXICOGENETICS;

RATTUS;

EID: 44349141288     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.01.036     Document Type: Article

References (34)

1. Casartelli A., Bonato M., Cristofori P., Crivellente F., Dal Negro G., Masotto I., Mutinelli C., Valko K., and Bonfante V. A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development. Cell Biol. Toxicol. 19 (2003) 161-176
2. Dennis Jr. G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., and Lempicki R.A. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 4 (2003) P3
3. Drenckhahn D., Kleine L., and Lullmann-Rauch R. Lysosomal alterations in cultured macrophages exposed to anorexigenic and psychotropic drugs. Lab. Invest. 35 (1976) 116-123
4. Drew R., Siddik Z.H., Mimnaugh E.G., and Gram T.E. Species and dose differences in the accumulation of imipramine by mammalian lungs. Drug Metab. Dispos. 9 (1981) 322-326
5. Fréneaux E., Labbe G., Letteron P., The Le Dinhi, Degott C., Genève J., Larrey D., and Pessayre D. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 8 (1988) 1056-1062
6. Halliwell W.H. Cationic amphiphilic drug-induced phospholipidosis. Toxicol. Pathol. 25 (1997) 53-60
7. Hansson A.L., Xia Z., Berglund M.C., Bergstrand A., Depierre J.W., and Nässberger L. Reduced cell survival and morphological alterations induced by three tricyclic antidepressants in human peripheral monocytes and lymphocytes and in cell lines derived from these cell types. Toxicol. In Vitro 11 (1997) 21-31
8. Honegger U.E., Zuehlke R.D., Scuntaro I., Schaefer M.H., Toplak H., and Wiesmann U.N. Cellular accumulation of amiodarone and desethylamiodarone in cultured human cells. Consequences of drug accumulation on cellular lipid metabolism and plasma membrane properties of chronically exposed cells. Biochem. Pharmacol. 45 (1993) 349-356
9. Hruban Z., Slesers A., and Hopkins E. Drug-induced and naturally occurring myeloid bodies. Lab. Invest. 27 (1972) 62-70
10. Inouye B., Yoshimura N., and Wachi T. Experimental studies on the mechanism of fatty liver formation induced by ethionamide. V. Liver and serum total cholesterol in ethionamide-administered rats. Kekkaku 48 (1973) 71-74
11. Joshi U.M., Rao P., Kodavanti S., Lockard V.G., and Mehendale H.M. Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: relevance to phospholipidosis. Biochim. Biophys. Acta 1004 (1989) 309-320
12. Kacew S. Cationic amphiphilic drug-induced renal cortical lysosomal phospholipidosis: an in vivo comparative study with gentamicin and chlorphentermine. Toxicol. Appl. Pharmacol. 91 (1987) 469-746
13. Kaloyanides G.J., and Pastoriza-Munoz E. Aminoglycoside nephrotoxicity. Kidney Int, 18 (1980) 571-582
14. Kasahara T., Tomita K., Murano H., Harada T., Tsubakimoto K., Ogihara T., Ohnishi S., and Kakinuma C. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicol. Sci. 90 (2006) 133-141
15. Kodavanti U.P., Lockard V.G., and Mehendale H.M. In vivo toxicity and pulmonary effects of promazine and chlorpromazine in rats. J. Biochem. Toxicol. 5 (1990) 245-251
16. Kuntz E., Liehr H., and Pfingst W. Toxic liver damage due to ethionamide. Ger. Med. Mon. 13 (1968) 599-602
17. Lake B.G. Investigations into the mechanism of coumarin-induced hepatotoxicity in the rat. Arch. Toxicol. Suppl. 7 (1984) 16-29
18. Laurent G., Kishore B.K., and Tulkens P.M. Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochem. Pharmacol. 40 (1990) 2383-2392
19. Morgan M.Y., Reshef R., Shah R.R., Oates N.S., Smith R.L., and Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 25 (1984) 1057-1064
20. Nioi P., Perry B.K., Wang E.J., Gu Y.Z., and Snyder R.D. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol. Sci. 99 (2007) 162-173
21. Pelletier D.J., Gehlhaar D., Tilloy-Ellul A., Johnson T.O., and Greene N. Evaluation of a published in silico model and construction of a novel bayesian model for predicting phospholipidosis inducing potential. J. Chem. Inf. Model 47 (2007) 1196-1205
22. Pessayre D., Bichara M., Degott C., Potet F., Benhamou J.P., and Feldmann G. Perhexiline maleate-induced cirrhosis. Gastroenterol. 76 (1979) 170-177
23. Pessayre D., and Larrey D. Acute and chronic drug-induced hepatitis. Baillieres Clin. Gastroenterol. 2 (1988) 385-422
24. Reasor M.J., and Kacew S. Drug-induced phospholipidosis: are there functional consequences?. Exp. Biol. Med. 226 (2001) 825-830
25. Reasor M.J., Hastings K.L., and Ulrich R.G. Drug-induced phospholipidosis: issues and future directions. Expert Opin. Drug Saf. 5 (2006) 567-583
26. Sawada H., Takami K., and Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 83 (2005) 282-292
27. Sawada H., Taniguchi K., and Takami K. Improved toxicogenomic screening for drug-induced phospholipidosis using a multiplexed quantitative gene expression ArrayPlate assay. Toxicol. In Vitro 20 (2006) 1506-1513
28. Takashima K., Mizukawa Y., Morishita K., Okuyama M., Kasahara T., Toritsuka N., Miyagishima T., Nagao T., and Urushidani T. Effect of the difference in vehicles on gene expression in the rat liver-analysis of the control data in the Toxicogenomics Project Database. Life Sci. 78 (2006) 2787-2796
29. Thielemann L.E., Bosco C., Rodrigo R., Orellana M., and Videla L.A. Effects of bromoethylamine on antioxidant capacity, lipid peroxidation, and morphological characteristics of rat liver. J. Biochem. Mol. Toxicol. 13 (1999) 47-52
30. Tomizawa K., Sugano K., Yamada H., and Horii I. Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. J. Toxicol. Sci. 31 (2006) 315-324
31. Urushidani T., and Nagao T. Toxicogenomics: the Japanese initiative. In: Borlak J. (Ed). Handbook of Toxicogenomics-Strategies and Applications (2005), Wiley-VCH 623-631
32. Weber L.W., Boll M., and Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. 33 (2003) 105-136
33. Whitehouse L.W., Menzies A., Mueller R., and Pontefract R. Ketoconazole-induced hepatic phospholipidosis in the mouse and its association with de-N-acetyl ketoconazole. Toxicology 94 (1994) 81-95
34. Xia Z., Ying G., Hansson A.L., Karlsson H., Xie Y., Bergstrand A., DePierre J.W., and Nassberger L. Antidepressant-induced lipidosis with special reference to tricyclic compounds. Prog. Neurobiol. 60 (2000) 501-512